Literature DB >> 15761416

Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system.

Emmilia Hodak1, Tirza Klein, Boaz Gabay, Dan Ben-Amitai, Reuven Bergman, Michael Gdalevich, Meora Feinmesser, Lea Maron, Michael David.   

Abstract

BACKGROUND: The familial occurrence of mycosis fungoides (MF) has been reported only in 8 families. Recently, the HLA class II alleles DRB1* 11 and DQB1* 03 have been found to be significantly increased for patients with sporadic MF, suggesting a possible immunogenetic basis for the pathogenesis of this malignancy.
OBJECTIVE: We sought to detect familial occurrences of MF, to describe familial features, and to investigate the possible association or linkage with the HLA system in such cases.
METHODS: The files of 300 patients with MF were reviewed to search for familial occurrence in at least two first-degree relatives. A group of 252 healthy unrelated individuals served as control subjects. Tissue typing for HLA class I was performed using the microlymphocytotoxicity technique. DNA-based analysis for DRB1* and DQB1* alleles was performed using polymerase chain reaction amplification.
RESULTS: Six families comprising 12 Jewish patients (9 male and 3 female) were detected: in 5, two first-degree relatives had MF; and in one, one member had MF and another had parapsoriasis en plaque. There were 5 families with two affected siblings and one family with a parent-child pair. In all but one family, the age of onset, clinical features, and response to therapy were similar to those in sporadic MF. One family, however, was exceptional: both affected siblings were children and both exhibited a similar but unusual morphology in the form of a hypopigmented variant of MF in conjunction with a psoriasiform variant. The allele frequency of HLA DQB1* 03 was found to be significantly greater among the patients than in the control group (66.7% vs 33%, respectively; P = .027), supporting an association of this allele with familial MF. Analysis of the HLA typing in the affected sibling pairs, when grouped together, did not support linkage to the HLA locus because no segregation distortion could be demonstrated ( P = .76).
CONCLUSIONS: Familial aggregation of MF among Israeli Jews may not be as rare as is reflected in the literature. This familial clustering, together with the detection of certain HLA class II alleles with this malignancy (sporadic and familial), suggests that genetic factors may play a role in MF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761416     DOI: 10.1016/j.jaad.2003.12.052

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  The Histological Spectrum of Early Mycosis Fungoides: A Study of 58 Saudi Arab patients.

Authors:  Maha Arafah; Shaesta Naseem Zaidi; Hala Kassouf Kfoury; Ammar Al Rikabi; Khalid Al Ghamdi
Journal:  Oman Med J       Date:  2012-03

2.  Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Youssef Habel; David R Risser; Pamela Gangar; Michelle A Jennings; Kevin Pehr; Victor G Prieto; Denis Sasseville; Madeleine Duvic
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

4.  The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).

Authors:  Ivan V Litvinov; Elena Netchiporouk; Brendan Cordeiro; Marc-André Doré; Linda Moreau; Kevin Pehr; Martin Gilbert; Youwen Zhou; Denis Sasseville; Thomas S Kupper
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

5.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

Review 6.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

7.  Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Michelle A Jennings; David R Risser; Pamela Gangar; Elena Netchiporouk; Linda Moreau; Victor G Prieto; Denis Sasseville; Madeleine Duvic
Journal:  Cancer Med       Date:  2015-07-01       Impact factor: 4.452

8.  Intravascular large B-cell lymphoma associated with silicone breast implant, HLA-DRB1*11:01, and HLA-DQB1*03:01 manifesting as macrophage activation syndrome and with severe neurological symptoms: a case report.

Authors:  Oswald Moling; Andrea Piccin; Martina Tauber; Peter Marinello; Mariagrazia Canova; Marco Casini; Giovanni Negri; Bernd Raffeiner; Raffaella Binazzi; Latha Gandini; Cinzia Vecchiato; Giovanni Rimenti; Atto Billio
Journal:  J Med Case Rep       Date:  2016-09-15

Review 9.  Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Charlotte Menne Bonefeld; Mariusz A Wasik; Sergei B Koralov; Carsten Geisler; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Toxins (Basel)       Date:  2013-08-14       Impact factor: 4.546

10.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.